Duchenne Market Gets Bleaker With Sarepta Eteplirsen Delay
This article was originally published in Scrip
Executive Summary
Adding to the already bleak outlook for the Duchenne muscular dystrophy (DMD) market, Sarepta Therapeutics Inc. on Feb. 8 disclosed the FDA was delaying its verdict on the company's experimental drug eteplirsen until May 26 – citing a "major amendment" to the new drug application (NDA) submitted by the company.